BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler sold 16,581 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $86.76, for a total value of $1,438,567.56. Following the completion of the transaction, the chief executive officer now directly owns 332,697 shares of the company’s stock, valued at approximately $28,864,791.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

John Oyler also recently made the following trade(s):

  • On Wednesday, November 29th, John Oyler sold 85,906 shares of BeiGene stock. The stock was sold at an average price of $84.66, for a total value of $7,272,801.96.
  • On Monday, November 13th, John Oyler sold 25,054 shares of BeiGene stock. The stock was sold at an average price of $83.06, for a total value of $2,080,985.24.
  • On Wednesday, November 15th, John Oyler sold 150,957 shares of BeiGene stock. The stock was sold at an average price of $80.50, for a total value of $12,152,038.50.

Shares of BeiGene, Ltd. (NASDAQ:BGNE) opened at $80.00 on Friday. BeiGene, Ltd. has a 52 week low of $26.43 and a 52 week high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.

BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same quarter last year, the business earned ($1.08) earnings per share. research analysts expect that BeiGene, Ltd. will post -3.09 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in BGNE. Hillhouse Capital Management Ltd. boosted its stake in BeiGene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after purchasing an additional 2,355,906 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in BeiGene in the third quarter worth $62,076,000. Janus Henderson Group PLC purchased a new position in BeiGene in the third quarter worth $33,744,000. Alliancebernstein L.P. purchased a new position in BeiGene in the second quarter worth $7,373,000. Finally, Employees Retirement System of Texas purchased a new position in shares of BeiGene in the second quarter valued at $2,855,000. Institutional investors own 55.33% of the company’s stock.

A number of analysts have commented on BGNE shares. Maxim Group set a $120.00 price target on shares of BeiGene and gave the company a “buy” rating in a research report on Tuesday, November 14th. Cowen restated a “buy” rating on shares of BeiGene in a research note on Tuesday, November 14th. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price objective (up from $58.00) on shares of BeiGene in a report on Tuesday, November 14th. Zacks Investment Research downgraded shares of BeiGene from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $96.67.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/john-oyler-sells-16581-shares-of-beigene-ltd-bgne-stock/1736568.html.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.